Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ACACB | O00763 | 6/20 | 0.53 |
| ▸ | ACACA | Q13085 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4322956 | 1.00 | HTT (0.62) | HTTNPC1ALDH1A1KDM4ELMNA | |
| SCHEMBL1615756 | 1.00 | HTT (0.62) | HTTNPC1ALDH1A1KDM4ELMNA | |
| SCHEMBL8300135 | 0.85 | HTT (0.58) | HTTNPC1ALDH1A1KDM4ELMNA | |
| SCHEMBL23000164 | 0.84 | HTT (0.62) | HTTNPC1ALDH1A1KDM4ELMNA | |
| SCHEMBL4451432 | 0.84 | HTT (0.62) | HTTNPC1ALDH1A1KDM4ELMNA | |
| SCHEMBL6174378 | 0.84 | HTT (0.62) | HTTNPC1ALDH1A1KDM4ELMNA | |
| SCHEMBL13778592 | 0.83 | ACACB (0.56) | ACACBACACA | |
| SCHEMBL4322952 | 0.82 | HTT (0.60) | HTTNPC1ALDH1A1KDM4ELMNA | |
| SCHEMBL8310592 | 0.82 | HTT (0.60) | HTTNPC1ALDH1A1KDM4ELMNA | |
| SCHEMBL19652074 | 0.82 | HTT (0.60) | HTTNPC1ALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923464-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2011-04-12 | — | — | US | disclosed |
| US-7923464-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2011-04-12 | — | — | US | disclosed |
| US-7923464-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2011-04-12 | — | — | US | disclosed |
| WO-2010055124-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010055126-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010055125-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010055125-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010055126-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010055124-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010055127-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2010-05-20 | — | — | WO | disclosed |
| EP-1996556-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH AS (DK) | 2009-11-18 | — | — | EP | disclosed |
| EP-1996556-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH AS (DK) | 2009-11-18 | — | — | EP | disclosed |
| US-20090048321-A1 | Benzimidazole Derivatives and Their Use for Modulating the GABA-Alpha Receptor Complex | ANIONA APS (DK) | 2009-02-19 | — | — | US | disclosed |
| US-20090048321-A1 | Benzimidazole Derivatives and Their Use for Modulating the GABA-Alpha Receptor Complex | ANIONA APS (DK) | 2009-02-19 | — | — | US | disclosed |
| US-20090048321-A1 | Benzimidazole Derivatives and Their Use for Modulating the GABA-Alpha Receptor Complex | ANIONA APS (DK) | 2009-02-19 | — | — | US | disclosed |
| EP-1996556-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NeuroSearch A/S (DK) | 2008-12-03 | — | — | EP | disclosed |
| CN-101291915-A | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH AS (DK) | 2008-10-22 | — | — | CN | disclosed |
| WO-2007065864-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007065864-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2007-06-14 | — | — | WO | disclosed |
| US-20070105832-A1 | Substituted azetidinones | Cadrenal Therapeutics, Inc. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105832-A1 | Substituted azetidinones | F2R, CPA3, CFD | HTT 3188/4885NPC1 3423/4885ALDH1A1 2503/4885 |
| US-20090048321-A1 | Benzimidazole Derivatives and Their Use for Modulating the GABA-Alpha Receptor Complex | GABRB1, GABRB2, GABRB3 | HTT 2412/4885NPC1 1879/4885ALDH1A1 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.